Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126977 | 0.91 | NAMPT (0.38) | NAMPTALDH1A1POLBEPHX2ATM | |
| SCHEMBL4118135 | 0.90 | NAMPT (0.42) | NAMPTALDH1A1EPHX2PTGDR2 | |
| SCHEMBL4126103 | 0.89 | ALDH1A1 (0.42) | NAMPTALDH1A1P2RX7CNR1 | |
| SCHEMBL4129210 | 0.88 | P2RX7 (0.37) | NAMPTALDH1A1P2RX7PTGDR2CNR1 | |
| SCHEMBL4123666 | 0.88 | ALDH1A1 (0.38) | NAMPTALDH1A1SLC6A9 | |
| SCHEMBL4119395 | 0.87 | KCNQ3 (0.35) | NAMPTALDH1A1CNR1CNR2 | |
| SCHEMBL4135433 | 0.86 | NAMPT (0.37) | NAMPTALDH1A1POLBATMSLC6A9 | |
| SCHEMBL4131207 | 0.85 | THRB (0.40) | NAMPTALDH1A1ATM | |
| SCHEMBL4131003 | 0.84 | NAMPT (0.37) | NAMPTALDH1A1ATMSLC6A9 | |
| SCHEMBL4125815 | 0.84 | ATM (0.36) | NAMPTALDH1A1POLBEPHX2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NAMPT 2129/4885ALDH1A1 1497/4885POLB 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.